AURINIA PHARMACEUTICALS INC (AUPH)

Data delayed 15 minutes

Trading terms

Trading hours (UTC)
Monday: 11:00 - 00:00
Tuesday - Friday: 00:00 - 00:30, 11:00 - 00:00
Saturday: 00:00 - 00:30

News

About

Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.

http://www.auriniapharma.com/
х
Risk warning: Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
Póngase en contacto con nosotrosColapso